Article info
PDFEBM analysis
Primary care
Was amorphous aluminium hydroxyphosphate sulfate adequately evaluated before authorisation in Europe?
- Correspondence to Dr Sesilje B Petersen, Dept. of Occupational and Environmental Medicine, Bispebjerg Hospital, Kobenhavn, Denmark; sesilje.elise.bondo.petersen{at}regionh.dk
Citation
Was amorphous aluminium hydroxyphosphate sulfate adequately evaluated before authorisation in Europe?
Publication history
- Accepted July 9, 2020
- First published August 6, 2020.
Online issue publication
January 10, 2023
Article Versions
- Previous version (7 January 2022).
- Previous version (7 January 2022).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.